Overview

An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder.

Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
This extension study is designed to investigate the long-term safety and tolerability of licarbazepine 750-2000 mg/day over 52 weeks in patients who completed the 3-week double-blind study CLIC477D2301.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis